The Importance Of Final Dosage Form For Clinical Trial Material

In Q4, 2019 ISR asked 100 outsourcers of clinical manufacturing how important it is for the clinical trial material, or IMP, to be in its final dosage form. 44% of respondents said it is very-extremely important for the IMP to be in the final dosage form. Another 47% said it is important. To learn how dosage form influences service provider selection and much more, follow the link to the Clinical Manufacturing Market Dynamics and Service Provider Benchmarking  report preview.